651 related articles for article (PubMed ID: 8625316)
41. Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets.
Moodie SA; Paris M; Villafranca E; Kirshmeier P; Willumsen BM; Wolfman A
Oncogene; 1995 Aug; 11(3):447-54. PubMed ID: 7630628
[TBL] [Abstract][Full Text] [Related]
42. RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.
Ladeda V; Frankel P; Feig LA; Foster DA; Bal de Kier Joffe E; Aguirre-Ghiso JA
Biochem Biophys Res Commun; 2001 May; 283(4):854-61. PubMed ID: 11350063
[TBL] [Abstract][Full Text] [Related]
43. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
[TBL] [Abstract][Full Text] [Related]
44. Ras regulatory interactions: novel targets for anti-cancer intervention?
Prendergast GC; Gibbs JB
Bioessays; 1994 Mar; 16(3):187-91. PubMed ID: 8166672
[TBL] [Abstract][Full Text] [Related]
45. The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways.
Hernandez-Muñoz I; Malumbres M; Leonardi P; Pellicer A
Oncogene; 2000 May; 19(23):2745-57. PubMed ID: 10851075
[TBL] [Abstract][Full Text] [Related]
46. The minimal fragments of c-Raf-1 and NF1 that can suppress v-Ha-Ras-induced malignant phenotype.
Fridman M; Tikoo A; Varga M; Murphy A; Nur-E-Kamal MS; Maruta H
J Biol Chem; 1994 Dec; 269(48):30105-8. PubMed ID: 7982912
[TBL] [Abstract][Full Text] [Related]
47. Ras- and Raf-mediated regulation of transforming growth factor beta 1 gene expression by ligands of tyrosine kinase receptors in PC12 cells.
Cosgaya JM; Aranda A
Oncogene; 1996 Jun; 12(12):2651-60. PubMed ID: 8700524
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells.
Michieli P; Li W; Lorenzi MV; Miki T; Zakut R; Givol D; Pierce JH
Oncogene; 1996 Feb; 12(4):775-84. PubMed ID: 8632899
[TBL] [Abstract][Full Text] [Related]
49. Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator.
Kishida S; Koyama S; Matsubara K; Kishida M; Matsuura Y; Kikuchi A
Oncogene; 1997 Dec; 15(24):2899-907. PubMed ID: 9416833
[TBL] [Abstract][Full Text] [Related]
50. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
Velasco JA; Avila MA; Notario V
Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
[TBL] [Abstract][Full Text] [Related]
51. Specific association of activated MAP kinase kinase kinase (Raf) with the plasma membranes of ras-transformed retinal cells.
Traverse S; Cohen P; Paterson H; Marshall C; Rapp U; Grand RJ
Oncogene; 1993 Nov; 8(11):3175-81. PubMed ID: 8414521
[TBL] [Abstract][Full Text] [Related]
52. RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein.
Wolthuis RM; Bauer B; van 't Veer LJ; de Vries-Smits AM; Cool RH; Spaargaren M; Wittinghofer A; Burgering BM; Bos JL
Oncogene; 1996 Jul; 13(2):353-62. PubMed ID: 8710374
[TBL] [Abstract][Full Text] [Related]
53. Rac1 and extracellularly regulated kinase activation are sufficient for E1A-dependent cooperative transformation of primary epithelial cells, but progression can only be modulated by E1A or Rac1.
Fischer RS; Zheng Y; Quinlan MP
Cell Growth Differ; 1998 Mar; 9(3):209-21. PubMed ID: 9543387
[TBL] [Abstract][Full Text] [Related]
54. Critical role of Rho in cell transformation by oncogenic Ras.
Prendergast GC; Khosravi-Far R; Solski PA; Kurzawa H; Lebowitz PF; Der CJ
Oncogene; 1995 Jun; 10(12):2289-96. PubMed ID: 7784077
[TBL] [Abstract][Full Text] [Related]
55. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G; Hauser CA
Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
[TBL] [Abstract][Full Text] [Related]
56. ralGDS family members interact with the effector loop of ras p21.
Kikuchi A; Demo SD; Ye ZH; Chen YW; Williams LT
Mol Cell Biol; 1994 Nov; 14(11):7483-91. PubMed ID: 7935463
[TBL] [Abstract][Full Text] [Related]
57. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
[TBL] [Abstract][Full Text] [Related]
58. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
Topol LZ; Marx M; Calothy G; Blair DG
Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484
[TBL] [Abstract][Full Text] [Related]
59. R-ras interacts with rasGAP, neurofibromin and c-raf but does not regulate cell growth or differentiation.
Rey I; Taylor-Harris P; van Erp H; Hall A
Oncogene; 1994 Mar; 9(3):685-92. PubMed ID: 8108110
[TBL] [Abstract][Full Text] [Related]
60. Signaling molecules that mediate the actions of FGF.
Demo SD; Kikuchi A; Peters KG; MacNicol AM; Muslin AJ; Williams LT
Princess Takamatsu Symp; 1994; 24():243-9. PubMed ID: 8983079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
